References

Filters: Akiyama-2019b is   [Clear All Filters]
H
Huang CF, Tseng KC, Cheng PN, et al. Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR). Clin Gastroenterol Hepatol. 2022;20(5):1151-1162. doi:10.1016/j.cgh.2021.07.037.
Hughes BL, Page CM, Kuller JA, Kuller JA. Hepatitis C in pregnancy: screening, treatment, and management. Am J Obstet Gynecol. 2017;217(5):B2-B12.
Hung CH, Wang JH, Hu TH, et al. Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol. 2010;16(18):2265-2271.
Hussein NR, Sidiq Z, Saleem M. Successful treatment of hepatitis c virus genotype 4 in renal transplant recipients with direct-acting antiviral agents. Am J Transplant. 2016;16(7):2237-2238.
I
AbbVie Inc. Viekira XR [package insert]. 2017.
Indolfi G, Easterbrook P, Dusheiko GM, et al. Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4:477-487.
Ingiliz P, Krznaric I, Stellbrink H-J, et al. Multiple hepatitis C virus (HCV) reinfections in HIV-positive men who have sex with men: no influence of HCV genotype switch or interleukin-28B genotype on spontaneous clearance: HCV reinfection in HIV-positive MSM. HIV Med. 2014;15(6):355-361.
Ingiliz P, Christensen S, Kimhofer T, et al. Sofosbuvir and ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus (HCV) infection in HCV-monoinfected and HIV-HCV-coinfected individuals: results from the German hepatitis C cohort (GECCO-01). Clin Infect Dis. 2016;63(10):1320-1324.
Ingiliz P, Martin TC, Rodger A, et al. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. J Hepatol. 2017;66(2):282-287.
Ioannou GN, Beste LA, Chang MF, et al. Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs national health care system. Gastroenterology. 2016;151(3):457-471.e5.
Isakov V, Chulanov V, Abdurakhmanov D, et al. Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden. Infect Dis (Lond). 2019;51(2):131-139. doi:10.1080/23744235.2018.1535186.
Isakov V, Gankina N, Morozov V, et al. Ledipasvir-sofosbuvir for 8 weeks in non-cirrhotic patients with previously untreated genotype 1 HCV Infection ± HIV-1 co-infection. Clin Drug Investig. 2018;38(3):239-247. doi:10.1007/s40261-017-0606-0.
Islam MM, Topp L, Conigrave KM, et al. Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre. J Subst Abuse Treat. 2012;43(4):440-445.
Islam N, Krajden M, Shoveller J, et al. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study. Lancet Gastroenterol Hepatol. 2017;2(3):200-210.
J
J D, VC DMaio, De Salazar A, et al. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. J Hepatol. 2021;74(4):801-810. doi:10.1016/j.jhep.2020.11.017.
Jacobson IM, Asante-Appiah E, Wong P, et al. Prevalence and impact of baseline NSA resistance associated variants (RAVs) on the efficacy of elbasvir/grazoprevir (EBR/GZR) against GT1a infection [abstract LB-22]. The Liver Meeting. 2015.
Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology. 2017;153(1):113-122.
Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867-1877.
Jacobson IM, Poordad F, Firpi-Morell R, Everson GT. Efficacy and Safety of Grazoprevir and Elbasvir in Hepatitis C Genotype 1-infected Patients with Child–Pugh class B cirrhosis (C-salt part A) [Abstract O008]. In: 50th Annual Meeting of the European Association for the Study of the Liver (EASL), April 22-26. 50th Annual Meeting of the European Association for the Study of the Liver (EASL), April 22-26. Vienna, Austria; 2015.
Jacobson IM, Poordad F, Firpi-Morell R, Firpi-Morell R. Elbasvir/grazoprevir in people with hepatitis C genotype 1 infection and Child-Pugh class B cirrhosis: the C-SALT study. Clin Transl Gastroenterol. 2019;10(4):e00007.
Top